WallStreetZenWallStreetZen

NASDAQ: TARA
Protara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TARA

Based on 3 analysts offering 12 month price targets for Protara Therapeutics Inc

Min Forecast
$26.00+692.68%
Avg Forecast
$27.00+723.17%
Max Forecast
$28.00+753.66%

Should I buy or sell TARA stock?

Based on 3 analysts offering ratings for Protara Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TARA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TARA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their TARA stock forecasts and price targets.

TARA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-20
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-04-29

1 of 1

Forecast return on equity

Is TARA forecast to generate an efficient return?

Company
24.01%
Industry
22.21%
Market
168.26%
TARA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TARA forecast to generate an efficient return on assets?

Company
21.99%
Industry
23.81%
TARA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TARA earnings per share forecast

What is TARA's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$1.51
Avg 2 year Forecast
-$1.67
Avg 3 year Forecast
-$0.62

TARA revenue forecast

What is TARA's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$1.2M
Avg 3 year Forecast
$66.5M

TARA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TARA$3.28$27.00+723.17%Strong Buy
ZNTL$2.70$9.00+233.33%Strong Buy
ADAG$2.93$8.67+195.80%Strong Buy
ORMP$4.73N/AN/A
NKTX$2.75$11.75+327.27%Strong Buy
View Top Biotech Stocks

Protara Therapeutics Stock Forecast FAQ

Is Protara Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: TARA) stock is to Strong Buy TARA stock.

Out of 3 analysts, 1 (33.33%) are recommending TARA as a Strong Buy, 2 (66.67%) are recommending TARA as a Buy, 0 (0%) are recommending TARA as a Hold, 0 (0%) are recommending TARA as a Sell, and 0 (0%) are recommending TARA as a Strong Sell.

If you're new to stock investing, here's how to buy Protara Therapeutics stock.

What is TARA's earnings growth forecast for 2026-2028?

(NASDAQ: TARA) Protara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.

Protara Therapeutics's earnings in 2026 is -$70,015,000.On average, 10 Wall Street analysts forecast TARA's earnings for 2026 to be -$88,985,986, with the lowest TARA earnings forecast at -$121,618,514, and the highest TARA earnings forecast at -$81,285,844. On average, 9 Wall Street analysts forecast TARA's earnings for 2027 to be -$98,512,178, with the lowest TARA earnings forecast at -$130,305,551, and the highest TARA earnings forecast at -$45,296,692.

In 2028, TARA is forecast to generate -$36,769,213 in earnings, with the lowest earnings forecast at -$53,280,492 and the highest earnings forecast at -$24,199,602.

What is TARA's revenue growth forecast for 2026-2028?

(NASDAQ: TARA) Protara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Protara Therapeutics's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast TARA's revenue for 2026 to be $0, with the lowest TARA revenue forecast at $0, and the highest TARA revenue forecast at $0. On average, 9 Wall Street analysts forecast TARA's revenue for 2027 to be $70,323,631, with the lowest TARA revenue forecast at $0, and the highest TARA revenue forecast at $434,351,837.

In 2028, TARA is forecast to generate $3,930,263,620 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $7,862,063,724.

What is TARA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TARA) forecast ROA is 21.99%, which is lower than the forecast US Biotechnology industry average of 23.81%.

What is TARA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year TARA price target, the average TARA price target is $27.00, with the highest TARA stock price forecast at $28.00 and the lowest TARA stock price forecast at $26.00.

On average, Wall Street analysts predict that Protara Therapeutics's share price could reach $27.00 by May 20, 2027. The average Protara Therapeutics stock price prediction forecasts a potential upside of 723.17% from the current TARA share price of $3.28.

What is TARA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TARA) Protara Therapeutics's current Earnings Per Share (EPS) is -$1.36. On average, analysts forecast that TARA's EPS will be -$1.51 for 2026, with the lowest EPS forecast at -$2.06, and the highest EPS forecast at -$1.38. On average, analysts forecast that TARA's EPS will be -$1.67 for 2027, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$0.77. In 2028, TARA's EPS is forecast to hit -$0.62 (min: -$0.90, max: -$0.41).

What is TARA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TARA) forecast ROE is 24.01%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.